SuperworthValion Bio revenue VBIO
Sales by quarter and over the last twelve months, from 2021.
- Last 12 months, to Sep 30, 2025
- $482K
- Latest quarter, Q3 FY25
- $146K
- +16% on a year earlier
- Fiscal year 2024
- $780K
- −34% on the year before
Valion Bio's revenue was $482K over the twelve months to Sep 30, 2025, down 50% on a year earlier.
In its latest quarter, Q3 FY25, it was $146K, up 16% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2024 | $780K | −34% |
| FY2023 | $1.2M | −36% |
| FY2022 | $1.8M | +46% |
| FY2021 | $1.3M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY25 | $146K | +16% | $482K | |
| Q2 FY25 | $86K | −39% | $462K | |
| Q1 FY25 | $70K | −79% | $516K | |
| Q4 FY24 | $180K | −50% | $780K | |
| Q3 FY24 | $126K | −55% | $957K | |
| Q2 FY24 | $140K | −13% | $1.1M | |
| Q1 FY24 | $334K | −11% | $1.1M | |
| Q4 FY23 | $357K | −13% | $1.2M | |
| Q3 FY23 | $282K | −41% | $1.2M | |
| Q2 FY23 | $161K | −70% | $1.4M | |
| Q1 FY23 | $376K | −12% | $1.8M | |
| Q4 FY22 | $408K | +5% | $1.8M |
Against its peers
Companies in Drug Manufacturers - General nearest Valion Bio's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| VBIOValion Bio | n/m | |
| NXTSNexentis Technologies | n/m | |
| LABTLakewood-Amedex Biotherapeutics | n/m | |
| JAGXJaguar Health | $27.8M | +136% a year |
| DCOYDecoy Therapeutics | n/m | |
| SBFMSunshine Biopharma | $35.3M | −3% a year |
| ARTLArtelo Biosciences | n/m | |
| LNAILunai Bioworks | n/m | |
| GNPXGenprex | n/m | |
| GOVXGeoVax Labs | $0 | −100% a year |
| ONCOOnconetix | n/m | |
| Peer median | $27.8M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Valion Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.